# DotBio Pte.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dotbio-pte

- Industry: Biotechnology
- Headquarters: Singapore, Singapore
- Website: www.dotbio.com
- Total disclosed funding: $3M
- Latest round: Series A (May 2, 2019)
- Investors on record: 3

## About

DotBio Pte. Ltd., based in Singapore, specializes in developing next-generation antibody therapies utilizing its proprietary DotBody technology platform, aimed at enhancing therapeutic outcomes in various disease areas.Founded in 2017 and headquartered in Singapore, DotBio Pte. Ltd. focuses on innovative antibody therapies. The company has completed 3 deals, with its most recent funding round on August 7, 2023, raising USD 5.6 mn in a pre-Series A round co-led by AIM-HI Accelerator Fund, Gaorong Capital, and Proxima Ventures, among others. Ignacio Asial serves as the CEO and founder of DotBio, driving its strategic vision and technology development.DotBio specializes in the development of next-generation antibody therapies utilizing its proprietary DotBody technology platform. This innovative platform is based on modular design, facilitating the prefabrication of antibody modules with specific functions. DotBio combines these modules on demand to create multi-functional antibodies, including bi- and tri-specific antibodies, antibody-drug conjugates (ADCs), and intracellular antibodies. This high-throughput process accelerates the development timeline, enabling the generation of complex antibody products within months. DotBio primarily serves pharmaceutical and biotechnology companies worldwide, focusing on markets such as North America, Europe, and Asia, addressing therapeutic areas including oncology and autoimmune diseases.In the most recent fiscal year, 2024, DotBio reported a revenue of USD 810,532.50 and an EBITDA of USD -1,113,268.30. The company generates revenue through partnerships and B2B transactions with pharmaceutical companies and research institutions, providing customized antibody therapies and related services. These transactions may include collaborative research agreements or licensing arrangements, structured around project-specific pricing, milestone payments, and royalties tied to commercial success.In August 2023, DotBio Pte. Ltd. raised USD 5.6 mn to scale operations and commence pre-clinical, chemical manufacturing, and control studies to validate its therapeutic drug candidates. The funding will support the launch of new antibody products in the coming years, aligning with the company's strategy to expand into new markets, particularly in Europe and Asia by 2025.

## Funding rounds

- Series A, May 2, 2019, $3M — ASLAN Pharmaceuticals Pte. Ltd., FuTechVC, NTUitive

## Investors

- ASLAN Pharmaceuticals Pte. Ltd. — Series A
- FuTechVC — Series A
- NTUitive (https://capitalatlas.ai/funds/ntuitive) — Series A